New CF Investigational Drug Enters Into Phase 1 Clinical Trials
December 4, 2008
A new investigational drug for cystic fibrosis, discovered with support from the CF Foundation, has entered into a Phase 1 clinical trial. The potential drug, GS9411, was co-developed by Gilead Sciences, Inc. and Parion Sciences, Inc., and was identified as part of a $1.7 million award to Parion through the Foundation’s Therapeutics Development Program. Going forward, Gilead will assume primary development responsibilities.
The Phase I clinical trial of this potential drug will be carried out in healthy volunteers to evaluate safety and tolerability. It is designed to increase airway hydration for the treatment of pulmonary disease.
Previously known as P-680, GS9411 is intended to decrease development of thick, sticky mucus in the lungs of CF patients, which often leads to severe infections that reduce lung function and cause irreversible lung damage.
Read the full release.